Nevertheless, we identified the CDK4/6 inhibition axis as a potential correlate of response in mUC and RCC tumors treated with atezolizumab, suggesting that subsets of tumors may share mechanisms of response and resistance to cancer immunotherapy. This evidence concerns the gene CDK4 and renal cell carcinoma.